2017 Q1 Form 10-K Financial Statement
#000156459018005224 Filed on March 12, 2018
Income Statement
| Concept | 2017 Q1 | 2017 | 2016 Q4 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $2.870M | $10.91M | $2.740M |
| YoY Change | 20.59% | 11.9% | 41.97% |
| % of Gross Profit | |||
| Research & Development | $7.610M | $30.26M | $6.500M |
| YoY Change | 41.71% | 48.02% | 3.83% |
| % of Gross Profit | |||
| Depreciation & Amortization | $3.302K | $11.09K | $10.00K |
| YoY Change | -23.56% | -32.89% | 0.0% |
| % of Gross Profit | |||
| Operating Expenses | $10.49M | $41.17M | $9.240M |
| YoY Change | 35.18% | 36.37% | 12.82% |
| Operating Profit | -$10.49M | -$9.237M | |
| YoY Change | 35.17% | 12.73% | |
| Interest Expense | -$201.5K | -$614.3K | -$170.0K |
| YoY Change | -25.47% | -40.35% | -32.0% |
| % of Operating Profit | |||
| Other Income/Expense, Net | |||
| YoY Change | |||
| Pretax Income | -$10.64M | -$40.90M | -$9.400M |
| YoY Change | 33.0% | 31.74% | 11.37% |
| Income Tax | -$9.400M | ||
| % Of Pretax Income | |||
| Net Earnings | -$10.64M | -$31.52M | -$9.404M |
| YoY Change | 32.99% | 1.54% | 11.44% |
| Net Earnings / Revenue | |||
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$300.8K | -$830.8K | -$269.5K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 35.29M | ||
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2017 Q1 | 2017 | 2016 Q4 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $85.40M | $128.2M | $83.00M |
| YoY Change | 91.48% | 54.46% | 157.76% |
| Cash & Equivalents | $68.89M | $26.10M | $83.06M |
| Short-Term Investments | $16.50M | $102.1M | $0.00 |
| Other Short-Term Assets | $900.0K | $1.400M | $900.0K |
| YoY Change | 28.57% | 55.56% | -30.77% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $86.20M | $129.5M | $83.90M |
| YoY Change | 90.29% | 54.35% | 150.59% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $0.00 | $100.0K | $0.00 |
| YoY Change | -100.0% | ||
| Goodwill | $14.87M | ||
| YoY Change | 0.0% | ||
| Intangibles | $34.20M | ||
| YoY Change | 0.0% | ||
| Long-Term Investments | $5.000M | ||
| YoY Change | |||
| Other Assets | $0.00 | ||
| YoY Change | |||
| Total Long-Term Assets | $49.10M | $54.20M | $49.04M |
| YoY Change | -0.06% | 10.61% | -0.11% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $86.20M | $129.5M | $83.90M |
| Total Long-Term Assets | $49.10M | $54.20M | $49.04M |
| Total Assets | $135.3M | $183.7M | $132.9M |
| YoY Change | 43.28% | 38.22% | 60.99% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $3.300M | $1.400M | $1.468M |
| YoY Change | 175.0% | -6.67% | 7.92% |
| Accrued Expenses | $4.800M | $1.400M | $3.400M |
| YoY Change | 54.84% | -58.82% | 36.0% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $5.000M | $4.000M | $4.900M |
| YoY Change | 92.31% | -18.37% | 250.0% |
| Total Short-Term Liabilities | $13.00M | $6.800M | $9.686M |
| YoY Change | 86.53% | -29.9% | 82.07% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $2.600M | $0.00 | $3.800M |
| YoY Change | -64.86% | -100.0% | -55.29% |
| Other Long-Term Liabilities | $41.20M | ||
| YoY Change | |||
| Total Long-Term Liabilities | $2.600M | $41.20M | $3.800M |
| YoY Change | -64.86% | 984.21% | -55.29% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $13.00M | $6.800M | $9.686M |
| Total Long-Term Liabilities | $2.600M | $41.20M | $3.800M |
| Total Liabilities | $29.00M | $52.10M | $26.96M |
| YoY Change | 4.32% | 92.96% | -1.09% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$132.9M | ||
| YoY Change | 30.49% | ||
| Common Stock | $238.8M | ||
| YoY Change | 52.0% | ||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $106.3M | $131.6M | $106.0M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $135.3M | $183.7M | $132.9M |
| YoY Change | 43.33% | 38.22% | 60.99% |
Cashflow Statement
| Concept | 2017 Q1 | 2017 | 2016 Q4 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$10.64M | -$31.52M | -$9.404M |
| YoY Change | 32.99% | 1.54% | 11.44% |
| Depreciation, Depletion And Amortization | $3.302K | $11.09K | $10.00K |
| YoY Change | -23.56% | -32.89% | 0.0% |
| Cash From Operating Activities | -$6.040M | $3.093M | -$8.930M |
| YoY Change | -0.17% | -112.04% | 35.3% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $52.40K | ||
| YoY Change | |||
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | -$16.48M | -$107.1M | $0.00 |
| YoY Change | -304.98% | -701.23% | -100.0% |
| Cash From Investing Activities | -$16.48M | -$107.2M | $0.00 |
| YoY Change | -304.98% | -701.51% | -100.0% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $389.00 | ||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 8.440M | 47.17M | 60.00K |
| YoY Change | -54.48% | -38.4% | |
| NET CHANGE | |||
| Cash From Operating Activities | -6.040M | 3.093M | -8.930M |
| Cash From Investing Activities | -16.48M | -107.2M | 0.000 |
| Cash From Financing Activities | 8.440M | 47.17M | 60.00K |
| Net Change In Cash | -14.08M | -56.93M | -8.870M |
| YoY Change | -168.58% | -182.87% | 247.84% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$6.040M | $3.093M | -$8.930M |
| Capital Expenditures | $52.40K | ||
| Free Cash Flow | $3.040M | ||
| YoY Change |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2016Q4 | nerv |
Deferred Related Party Revenue Current
DeferredRelatedPartyRevenueCurrent
|
2547952 | |
| CY2016Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
9685859 | |
| CY2016 | us-gaap |
Operating Expenses
OperatingExpenses
|
30190696 | |
| CY2017Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-164381441 | |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
100000000 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
125000000 | |
| CY2016Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2017Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2015 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-15853 | |
| CY2015 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
96910 | |
| CY2015 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2202235 | |
| CY2016 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-30190696 | |
| CY2015 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-26109619 | |
| CY2016 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-31045372 | |
| CY2015 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.16 | |
| CY2017 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.83 | |
| CY2015 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-27081632 | |
| CY2016 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.99 | |
| CY2017 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
1130544 | |
| CY2016 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
3832004 | |
| CY2016Q4 | us-gaap |
Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
|
815813 | |
| CY2017Q4 | us-gaap |
Liabilities
Liabilities
|
52101114 | |
| CY2017Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2016Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2016Q4 | us-gaap |
Liabilities
Liabilities
|
26960681 | |
| CY2017Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
29878 | |
| CY2016Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2017Q4 | us-gaap |
Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
|
5022982 | |
| CY2017Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2016Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
34200000 | |
| CY2016Q4 | us-gaap |
Goodwill
Goodwill
|
14869399 | |
| CY2016Q4 | us-gaap |
Assets
Assets
|
132942889 | |
| CY2016Q4 | us-gaap |
Notes Payable Current
NotesPayableCurrent
|
4853753 | |
| CY2016Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1468341 | |
| CY2017Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
3875 | |
| CY2016Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
3502 | |
| CY2017Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
295975010 | |
| CY2016Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
238836940 | |
| CY2017Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
| CY2016Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
| CY2016Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
100000000 | |
| CY2017Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
14808 | |
| CY2016Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-132858234 | |
| CY2015Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
55319557 | |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2016Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2016Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2016Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
125000000 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
38749343 | |
| CY2016Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
35024002 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
38749343 | |
| CY2016Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
35024002 | |
| CY2016 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
20439994 | |
| CY2015 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
18533363 | |
| CY2016 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
9750702 | |
| CY2015 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
7576256 | |
| CY2015 | us-gaap |
Operating Expenses
OperatingExpenses
|
26109619 | |
| CY2017 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-614264 | |
| CY2017Q4 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
41175600 | |
| CY2017 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-31523207 | |
| CY2015 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-1053070 | |
| CY2016 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
198453 | |
| CY2017 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
941833 | |
| CY2016 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-1029734 | |
| CY2017 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
0 | |
| CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
131597444 | |
| CY2016Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
105982208 | |
| CY2017Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
183698558 | |
| CY2016Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
132942889 | |
| CY2015 | us-gaap |
Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
|
166344 | |
| CY2017 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-40899479 | |
| CY2016 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-31045372 | |
| CY2015 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-27081632 | |
| CY2017 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-9376272 | |
| CY2017 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
37937191 | |
| CY2016 | nerv |
Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
|
23392098 | |
| CY2016 | us-gaap |
Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
|
-102632 | |
| CY2015 | us-gaap |
Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
|
-247262 | |
| CY2017 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
5033123 | |
| CY2016 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
3571211 | |
| CY2015 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2202235 | |
| CY2017 | us-gaap |
Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
|
-9376272 | |
| CY2015 | nerv |
Increase Decrease In Prepaid Expense Other Current Assets
IncreaseDecreaseInPrepaidExpenseOtherCurrentAssets
|
400037 | |
| CY2017 | nerv |
Increase Decrease In Prepaid Expense Other Current Assets
IncreaseDecreaseInPrepaidExpenseOtherCurrentAssets
|
306996 | |
| CY2016 | nerv |
Increase Decrease In Prepaid Expense Other Current Assets
IncreaseDecreaseInPrepaidExpenseOtherCurrentAssets
|
-372655 | |
| CY2017 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-32705 | |
| CY2016 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
107772 | |
| CY2015 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
718756 | |
| CY2016 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
76724 | |
| CY2017 | us-gaap |
Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
|
389 | |
| CY2017 | nerv |
Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
|
9356833 | |
| CY2017 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
5033123 | |
| CY2017 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
11094 | |
| CY2016 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
16530 | |
| CY2015 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
17276 | |
| CY2017 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
206562 | |
| CY2016 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
347771 | |
| CY2015 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
377455 | |
| CY2017 | us-gaap |
Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
|
185488 | |
| CY2017 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
624035 | |
| CY2016 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-1708825 | |
| CY2015 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
879380 | |
| CY2016 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
17818000 | |
| CY2015 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-18329588 | |
| CY2017 | nerv |
Gross Proceeds From Issuance Of Common Stock
GrossProceedsFromIssuanceOfCommonStock
|
44562500 | |
| CY2016 | nerv |
Gross Proceeds From Issuance Of Common Stock
GrossProceedsFromIssuanceOfCommonStock
|
57499995 | |
| CY2017 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
2944168 | |
| CY2017 | us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
389 | |
| CY2016 | us-gaap |
Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
|
999999 | |
| CY2015 | us-gaap |
Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
|
30999999 | |
| CY2015 | nerv |
Costs Paid In Connection With Private Placement
CostsPaidInConnectionWithPrivatePlacement
|
2466984 | |
| CY2017 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
9356833 | |
| CY2016 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
23392098 | |
| CY2017 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
1130544 | |
| CY2017 | us-gaap |
Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
|
-2547952 | |
| CY2016 | us-gaap |
Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
|
2547952 | |
| CY2015 | us-gaap |
Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
|
-1222420 | |
| CY2017 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
41175600 | |
| CY2017 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
14808 | |
| CY2017 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
29878 | |
| CY2015 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
-7694 | |
| CY2017 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
3092864 | |
| CY2016 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-25687674 | |
| CY2015 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-24269419 | |
| CY2017 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
134525859 | |
| CY2015 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
23279285 | |
| CY2017 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
27390000 | |
| CY2016 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
17818000 | |
| CY2015 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
4994683 | |
| CY2015 | us-gaap |
Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
|
44986 | |
| CY2017 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
52400 | |
| CY2017 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-107188259 | |
| CY2016 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
76724 | |
| CY2015 | us-gaap |
Proceeds From Notes Payable
ProceedsFromNotesPayable
|
10000000 | |
| CY2015 | us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
195656 | |
| CY2017 | us-gaap |
Repayments Of Senior Debt
RepaymentsOfSeniorDebt
|
4938713 | |
| CY2016 | us-gaap |
Repayments Of Senior Debt
RepaymentsOfSeniorDebt
|
1570583 | |
| CY2017 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
47166607 | |
| CY2016 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
76566229 | |
| CY2015 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
38337359 | |
| CY2017 | us-gaap |
Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
|
-56928788 | |
| CY2016 | us-gaap |
Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
|
68696555 | |
| CY2015 | us-gaap |
Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
|
-4261648 | |
| CY2015Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
14284054 | |
| CY2014Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
18545702 | |
| CY2017 | us-gaap |
Interest Paid
InterestPaid
|
436717 | |
| CY2016 | us-gaap |
Interest Paid
InterestPaid
|
691227 | |
| CY2015 | us-gaap |
Interest Paid
InterestPaid
|
616875 | |
| CY2017 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 1 — NATURE OF OPERATIONS AND LIQUIDITY </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Nature of Operations </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minerva Neurosciences, Inc. (“Minerva” or the “Company”) is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system, or CNS, diseases. The Company has acquired or in-licensed four development-stage proprietary compounds that it believes have innovative mechanisms of action and therapeutic profiles that may potentially address the unmet needs of patients with these diseases. The Company’s lead product candidate is roluperidone (also known as MIN-101), a compound the Company is developing for the treatment of schizophrenia. In addition, the Company’s portfolio includes seltorexant (also known as MIN-202 or JNJ-42847922), a compound the Company is co-developing with Janssen Pharmaceutica NV (“Janssen”) for the treatment of insomnia disorder and major depressive disorder (“MDD”); MIN-117, a compound the Company is developing for the treatment of MDD; and MIN-301, a compound the Company is developing for the treatment of Parkinson’s disease.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2013, the Company merged with Sonkei Pharmaceuticals Inc. (“Sonkei”), a clinical-stage biopharmaceutical company and, in February 2014, the Company acquired Mind-NRG, a pre-clinical-stage biopharmaceutical company. The Company refers to these transactions as the Sonkei Merger and Mind-NRG Acquisition, respectively. The Company holds licenses to roluperidone and MIN-117 from Mitsubishi Tanabe Pharma Corporation (“MTPC”) with the rights to develop, sell and import roluperidone and MIN-117 globally, excluding most of Asia. With the acquisition of Mind-NRG, the Company obtained exclusive rights to develop and commercialize MIN-301. The Company has also entered into a co-development and license agreement with Janssen, for the exclusive right to commercialize, and the co-exclusive right (with Janssen and its affiliates) to use and develop, seltorexant in the European Union, Switzerland, Liechtenstein, Iceland and Norway (the “Minerva Territory”), subject to certain royalty payments to Janssen, and royalty rights for any sales outside the Minerva Territory.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has limited capital resources and has incurred recurring operating losses and negative cash flows from operations since inception. As of December 31, 2017, the Company has an accumulated deficit of approximately <font style="color:#000000;">$164.4 million and net cash provided by operating activities was approximately $3.1 million during the year ended December 31, 2017. </font>Management expects to continue to incur operating losses and negative cash flows from operations. The Company has financed its operations to date from proceeds from the sale of common stock, warrants, loans and convertible promissory notes.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2017, the Company had cash, cash equivalents and marketable securities (current and non-current) of $133.2 million. During the year ended December 31, 2017, the Company received approximately $41.6 million in net proceeds from a July 2017 public offering of common stock (see Note 7), proceeds from the exercise of common stock warrants of $9.4 million (see Note 7) and $30 million in an upfront payment in connection with the Company’s amended Co-Development and License Agreement with Janssen for seltorexant (see Note 6). </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes that its existing cash, cash equivalents and marketable securities (current and non-current) will be sufficient to meet its cash commitments for at least the next 12 months after the date that the financial statements are issued. The process of drug development can be costly and the timing and outcomes of clinical trials is uncertain. The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to change. The actual amount of the Company’s expenditures will vary depending upon a number of factors including but not limited to the design, timing and duration of future clinical trials, the progress of the Company’s research and development programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based on the timing of future clinical trials which will be predicated upon adequate funding to complete the trials.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will need to raise additional capital in order to continue to fund operations and fully fund later stage clinical development programs. The Company believes that it will be able to obtain additional working capital through equity financings or other arrangements to fund future operations; however, there can be no assurance that such additional financing, if available, can be obtained on terms acceptable to the Company.  If the Company is unable to obtain such additional financing, future operations would need to be scaled back or discontinued.</p></div> | |
| CY2017 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="margin-bottom:0pt;margin-top:12pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. </p></div> | |
| CY2017 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div> <p style="margin-bottom:0pt;margin-top:12pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of credit risk </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and marketable securities (current and non-current). The Company maintains its cash and cash equivalent balances in the form of business checking accounts and money market accounts, the balances of which, at times, may exceed federally insured limits. Exposure to cash and cash equivalents credit risk is reduced by placing such deposits with major financial institutions and monitoring their credit ratings. Marketable securities consist primarily of corporate bonds, with fixed interest rates. Exposure to credit risk of marketable securities is reduced by maintaining a diverse portfolio and monitoring their credit ratings. </p></div> | |
| CY2017Q4 | us-gaap |
Held To Maturity Securities Amortized Cost Before Other Than Temporary Impairment
HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment
|
107132401 | |
| CY2017Q4 | us-gaap |
Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
|
131028 | |
| CY2017 | us-gaap |
Revenue Recognition Deferred Revenue
RevenueRecognitionDeferredRevenue
|
<div> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;text-indent:2.27%;">Deferred revenue</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies the revenue recognition guidance in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 605, Revenue Recognition. Using FASB ASC 605, Revenue that is unearned is deferred. Deferred revenue expected to be recognized as revenue more than one year subsequent to the balance sheet date is classified as long-term deferred revenue. </p></div> | |
| CY2017Q4 | us-gaap |
Held To Maturity Securities
HeldToMaturitySecurities
|
107132401 | |
| CY2017 | us-gaap |
Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
|
0 | |
| CY2016 | us-gaap |
Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
|
0 | |
| CY2015 | us-gaap |
Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
|
0 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.34 | |
| CY2017 | nerv |
Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit
TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit
|
-9400000 | |
| CY2017 | us-gaap |
Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
|
P3Y | |
| CY2016 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
0 | |
| CY2017 | us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
0 | |
| CY2016 | us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
0 | |
| CY2017Q4 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
129915027 | |
| CY2017 | us-gaap |
Revenues
Revenues
|
0 | |
| CY2017 | nerv |
Marketable Securities Weighted Average Remaining Maturity
MarketableSecuritiesWeightedAverageRemainingMaturity
|
P4M24D | |
| CY2017Q4 | us-gaap |
Investments And Cash
InvestmentsAndCash
|
133200000 | |
| CY2017 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2017Q4 | nerv |
Accrued Research And Development Costs And Other Expenses Current
AccruedResearchAndDevelopmentCostsAndOtherExpensesCurrent
|
1162441 | |
| CY2016Q4 | nerv |
Accrued Research And Development Costs And Other Expenses Current
AccruedResearchAndDevelopmentCostsAndOtherExpensesCurrent
|
574290 | |
| CY2017Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
251000 | |
| CY2016Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
192000 | |
| CY2017Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
20508 | |
| CY2016Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
49523 | |
| CY2017Q4 | us-gaap |
Accrued Bonuses Current
AccruedBonusesCurrent
|
5899 | |
| CY2016Q1 | us-gaap |
Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
|
1000000 | |
| CY2015Q1 | us-gaap |
Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
|
31000000 | |
| CY2015Q1 | us-gaap |
Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
|
200000 | |
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
4.98 | |
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
700000 | |
| CY2016 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
100000 | |
| CY2015 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
0 | |
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.00 | |
| CY2017 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
5033123 | |
| CY2016 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3571211 | |
| CY2015 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2202235 | |
| CY2017 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
-9376272 | |
| CY2016 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | |
| CY2015 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
18265530 | |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
20213845 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
145115 | |
| CY2017Q4 | us-gaap |
Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
|
0 | |
| CY2016Q4 | us-gaap |
Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
|
0 | |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
145115 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.2299 | |
| CY2016 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.0000 | |
| CY2015 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.0000 | |
| CY2017 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
-9900000 | |
| CY2016 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
11900000 | |
| CY2017Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
0 | |
| CY2016Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
0 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
14858509 | |
| CY2016Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
16413906 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
4180651 | |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
4741558 | |
| CY2017Q4 | nerv |
Deferred Tax Assets Deferred Start Up And License Costs
DeferredTaxAssetsDeferredStartUpAndLicenseCosts
|
6532419 | |
| CY2016Q4 | nerv |
Deferred Tax Assets Deferred Start Up And License Costs
DeferredTaxAssetsDeferredStartUpAndLicenseCosts
|
10258431 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
|
3053174 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
129082 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
47164480 | |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
51772855 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
41878528 | |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
51772855 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
5285952 | |
| CY2017Q4 | us-gaap |
Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
|
9343440 | |
| CY2016Q4 | us-gaap |
Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
|
13433760 | |
| CY2017Q4 | us-gaap |
Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
|
4057488 | |
| CY2016Q4 | us-gaap |
Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
|
13433760 | |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.3400 | |
| CY2015 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.3400 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
|
0.0066 | |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
|
0.0076 | |
| CY2015 | us-gaap |
Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
|
0.0053 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.0000 | |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
-0.0516 | |
| CY2015 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
-0.0520 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
0.5633 | |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
0.3840 | |
| CY2015 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
0.3867 | |
| CY2017Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-10485000 | |
| CY2017Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-9746000 | |
| CY2017Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-11407000 | |
| CY2017Q4 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-9532000 | |
| CY2017Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10645000 | |
| CY2017Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9780000 | |
| CY2017Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-11260000 | |
| CY2017Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
162000 | |
| CY2017Q1 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-0.30 | |
| CY2017Q2 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-0.27 | |
| CY2017Q3 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-0.28 | |
| CY2017Q4 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
0.00 | |
| CY2016Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-7757000 | |
| CY2016Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-4965000 | |
| CY2016Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-8232000 | |
| CY2016Q4 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-9237000 | |
| CY2016Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8004000 | |
| CY2016Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-5214000 | |
| CY2016Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8423000 | |
| CY2016Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9404000 | |
| CY2016Q1 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-0.29 | |
| CY2016Q2 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-0.18 | |
| CY2016Q3 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-0.24 | |
| CY2016Q4 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-0.27 | |
| CY2015Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-5878000 | |
| CY2015Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-6332000 | |
| CY2015Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-5705000 | |
| CY2015Q4 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-8194000 | |
| CY2015Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-6093000 | |
| CY2015Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-6610000 | |
| CY2015Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-5939000 | |
| CY2015Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8439000 | |
| CY2015Q1 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-0.31 | |
| CY2015Q2 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-0.27 | |
| CY2015Q3 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-0.24 | |
| CY2015Q4 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-0.34 |
